Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Ann M Tigges"'
Autor:
Eric L Haseltine, Sandra De Meyer, Inge Dierynck, Doug J Bartels, Anne Ghys, Andrew Davis, Eileen Z Zhang, Ann M Tigges, Joan Spanks, Gaston Picchio, Tara L Kieffer, James C Sullivan
Publikováno v:
PLoS Computational Biology, Vol 10, Iss 8, p e1003772 (2014)
For patients infected with hepatitis C virus (HCV), the combination of the direct-acting antiviral agent telaprevir, pegylated-interferon alfa (Peg-IFN), and ribavirin (RBV) significantly increases the chances of sustained virologic response (SVR) ov
Externí odkaz:
https://doaj.org/article/f5ba491c6dc148a48b13079d6909770f
Autor:
Tara L. Kieffer, James C. Sullivan, Sandra De Meyer, Jennifer Dorrian, I. Dierynck, Maria Beumont, Eileen Z. Zhang, Gaston Picchio, Stefan Zeuzem, Emily C. Martin, Doug J. Bartels, Anne Ghys, Joan Spanks, Ann M. Tigges, Ira M. Jacobson, Kenneth E. Sherman, Nathalie Adda
Publikováno v:
Clinical Infectious Diseases. 57:221-229
Background Telaprevir (TVR), a hepatitis C virus (HCV) NS3/4A protease inhibitor, has been approved to treat genotype 1 HCV. To understand the clinical impact of TVR-resistant variants, we analyzed samples from patients in phase 3 clinical trials to
Autor:
Ann D. Kwong, Tara L. Kieffer, Ann M. Tigges, Thomas Pfeiffer, Bambang S. Adiwijaya, Randal Byrn, Doug J. Bartels, Michelle Marcial, Yi Zhou, Eileen Z. Zhang, Chao Lin
Publikováno v:
The Journal of Infectious Diseases. 198:800-807
The prevalence and clinical implications of naturally occurring variants that are resistant to hepatitis C virus (HCV) protease inhibitors in treatment-naive patients has not been reported. We report here the prevalence of such variants and their eff
Phenotypic Characterization of Resistant Val 36 Variants of Hepatitis C Virus NS3-4A Serine Protease
Autor:
Ann D. Kwong, Hui-May Chu, Brian L. Hanzelka, Yunyi Wei, Yi Zhou, Doug J. Bartels, Chao Lin, Lora Swenson, Ute Müh, Ann M. Tigges, Debra L. Brennan, B. Govinda Rao
Publikováno v:
Antimicrobial Agents and Chemotherapy. 52:110-120
In patients chronically infected with hepatitis C virus (HCV) strains of genotype 1, rapid and dramatic antiviral activity has been observed with telaprevir (VX-950), a highly selective and potent inhibitor of the HCV NS3-4A serine protease. HCV vari
Autor:
Lora Swenson, Chao Lin, Ute Müh, Yunyi Wei, B.G. Rao, Ann M. Tigges, Ann D. Kwong, Doug J. Bartels, Brian L. Hanzelka, Yi Zhou, Debra L. Brennan
Publikováno v:
Journal of Biological Chemistry. 282:22619-22628
Telaprevir (VX-950) is a highly selective, potent inhibitor of the hepatitis C virus (HCV) NS3·4A serine protease. It has demonstrated strong antiviral activity in patients chronically infected with genotype 1 HCV when dosed alone or in combination
Autor:
Min Jiang, Tara L. Kieffer, Andrzej Ardzinski, Michelle Nelson, Andrew P. Davis, Eileen Z. Zhang, B. Govinda Rao, Olivier Nicolas, Joan Spanks, James C. Sullivan, Doug J. Bartels, Jennifer Dorrian, Ann M. Tigges, Rene Rijnbrand
VX-222, a thiophene-2-carboxylic acid derivative, is a selective nonnucleoside inhibitor of the hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase. In phase 1 and 2 clinical studies, VX-222 demonstrated effective antiviral efficacy, with subst
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85a520c3c8781b6778d91580e913667d
https://europepmc.org/articles/PMC4135882/
https://europepmc.org/articles/PMC4135882/
Autor:
Ann D. Kwong, Tara L. Kieffer, Gaston Picchio, James C. Sullivan, Elizabeth Dondero, Sandra De Meyer, Eileen Z. Zhang, Ann M. Tigges, Doug J. Bartels, Darin Takemoto, Jennifer Dorrian
Publikováno v:
Journal of virology. 87(3)
The prevalence of naturally occurring hepatitis C virus (HCV) variants that are less sensitive to direct-acting antiviral (DAA) inhibitors has not been fully characterized. We used population sequence analysis to assess the frequency of such variants
Autor:
Ann D. Kwong, Tara L. Kieffer, Jennifer Dorrian, Eileen Z. Zhang, Doug J. Bartels, James C. Sullivan, Ann M. Tigges
Publikováno v:
Virology Journal
Virology Journal, Vol 9, Iss 1, p 147 (2012)
Virology Journal, Vol 9, Iss 1, p 147 (2012)
Background Development of compensatory mutations within the HIV p7/p1 and p1/p6 protease cleavage site region has been observed in HIV-infected patients treated with protease inhibitors. Mechanisms of fitness compensation may occur in HCV populations
Autor:
Ann D. Kwong, Tara L. Kieffer, Jennifer Dorrian, James C. Sullivan, Sandra De Meyer, Stefan Zeuzem, Ann M. Tigges, Ira M. Jacobson, Gaston Picchio, Eileen Z. Zhang, Min Jiang, Maria Beumont, Joan Spanks, Doug J. Bartels, Nathalie Adda, Robert S. Kauffman, Kenneth E. Sherman, Anne Ghys, I. Dierynck, Bambang S. Adiwijaya
Publikováno v:
PLoS ONE
PLoS ONE, Vol 7, Iss 4, p e34372 (2012)
PLoS ONE, Vol 7, Iss 4, p e34372 (2012)
BackgroundIn patients with genotype 1 chronic hepatitis C infection, telaprevir (TVR) in combination with peginterferon and ribavirin (PR) significantly increased sustained virologic response (SVR) rates compared with PR alone. However, genotypic cha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25512938efa07686c5310b268770136f
http://publikationen.ub.uni-frankfurt.de/files/24292/journal.pone.0034372.pdf
http://publikationen.ub.uni-frankfurt.de/files/24292/journal.pone.0034372.pdf
Autor:
Douglas J. Bartels, Julian Symons, Tara L. Kieffer, Eileen Z. Zhang, Ann M. Tigges, J. Fry, A. Davis, J. Dorrian, Joan Spanks
Publikováno v:
Journal of Hepatology. 60:S496-S497